Nuformix PLC (LON:NFX) shares were down 2.5% during trading on Wednesday . The company traded as low as GBX 5.66 ($0.07) and last traded at GBX 5.85 ($0.08), approximately 2,637,248 shares traded hands during trading. An increase of 133% from the average daily volume of 1,130,000 shares. The stock had previously closed at GBX 6 ($0.08).
The stock has a 50 day simple moving average of GBX 7.73 and a 200 day simple moving average of GBX 8. The company has a quick ratio of 0.47, a current ratio of 0.47 and a debt-to-equity ratio of 0.38. The company has a market cap of $28.67 million and a price-to-earnings ratio of -29.25.
In related news, insider David Tapolczay sold 650,000 shares of the firm’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of GBX 9 ($0.12), for a total transaction of £58,500 ($76,953.43).
Nuformix plc develops pharmaceutical products using its cocrystal technology in the United Kingdom. Its lead programs include NXP001, which is used for oncology supportive care; and NXP002 for use in the treatment of fibrosis. The company is also developing NXP003, which is under the pre-clinical stage for the treatment of anti-inflammatory diseases.
Featured Story: Stocks at 52 Week High
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.